GlassScriptPhysician profile
Jamie E Garcia
NPI 1760638712
$41,447.35
in general payments reported to CMS, 2019-2025
12 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $245 · 2021: $267 · 2022: $362 · 2023: $31K · 2024: $9,137 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $9,534 · Food and Beverage: $2,861 · Honoraria: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,710.00 |
| Travel and Lodging | $9,534.16 |
| Food and Beverage | $2,861.10 |
| Honoraria | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $38,971.21 | 2023-2024 | Igalmi |
| Janssen Pharmaceuticals, INC | $1,093.11 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $805.36 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $148.35 | 2020-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.99 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $110.09 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neuronetics, INC. | $67.80 | 2023 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $50.89 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $25.41 | 2019 | |
| Abbvie INC. | $20.88 | 2025 | |
| Noven Therapeutics, LLC | $15.97 | 2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $15.29 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.